45 results on '"Min-lian, Du"'
Search Results
2. Associations between serum apelin-12 levels and obesity-related markers in Chinese children.
- Author
-
Hong-Jun Ba, Hong-Shan Chen, Zhe Su, Min-Lian Du, Qiu-Li Chen, Yan-Hong Li, and Hua-Mei Ma
- Subjects
Medicine ,Science - Abstract
OBJECTIVE: To investigate possible correlations between apelin-12 levels and obesity in children in China and associations between apelin-12 and obesity-related markers, including lipids, insulin sensitivity and insulin resistance index (HOMA-IR). METHODS: Forty-eight obese and forty non-obese age- and gender-matched Chinese children were enrolled between June 2008 and June 2009. Mean age was 10.42 ± 2.03 and 10.86±2.23 years in obesity and control groups, respectively. Main outcome measures were apelin-12, BMI, lipids, glucose and insulin. HOMA-IR was calculated for all subjects. RESULTS: All obesity group subjects had significantly higher total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), insulin levels and HOMA-IR (all P
- Published
- 2014
- Full Text
- View/download PDF
3. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies
- Author
-
Min-lian Du, Hongwei Du, Ling Hou, Zhe Su, Shuixian Shen, G P Dong, Chun Xiu Gong, Yuchuan Li, Zhuhui Zhao, Li Liang, Chaoying Yan, and Xiaoping Luo
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Phases of clinical research ,030209 endocrinology & metabolism ,law.invention ,Growth hormone deficiency ,Polyethylene Glycols ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Randomized controlled trial ,law ,Internal medicine ,Clinical endpoint ,Medicine ,Humans ,Adverse effect ,Child ,Dwarfism, Pituitary ,business.industry ,Human Growth Hormone ,Human growth hormone ,General Medicine ,medicine.disease ,Recombinant Proteins ,Clinical trial ,030104 developmental biology ,Long acting ,Delayed-Action Preparations ,Clinical Study ,Female ,business - Abstract
Objective We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). Design Phase II and III, multicenter, open-label, randomized controlled trials. Methods 108 and 343 children with treatment-naive GHD from 6 hospitals in China were enrolled in the phase II and III studies respectively. Patients in the phase II study were randomized 1:1:1 to weekly Jintrolong (0.1 mg/kg/week PEG-rhGH complex), weekly Jintrolong (0.2 mg/kg/week PEG-rhGH complex) or daily rhGH (0.25 mg/kg/week) for 25 weeks. Patients in the phase III study were randomized in a 2:1 ratio to weekly Jintrolong (0.2 mg/kg/week) or daily rhGH (0.25 mg/kg/week) for 25 weeks. The primary endpoint for both studies was height velocity (HV) increase at the end of treatment. Other growth-related parameters, safety and compliance were also monitored. Results The phase II study established the preliminary efficacy, safety and recommended dose of Jintrolong PEG-rhGH. In the phase III study, we demonstrated significantly greater HV increases in patients receiving Jintrolong treatment (from 2.26 ± 0.87 cm/year to 13.41 ± 3.72 cm/year) vs daily rhGH (from 2.25 ± 0.82 cm/year to 12.55 ± 2.99 cm/year) at the end of treatment (P P Conclusion Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH.
- Published
- 2017
4. Therapeutic effects of growth hormone combined with low-dose stanozolol on growth velocity and final height of girls with Turner syndrome
- Author
-
Hong-shan Chen, Min-Lian Du, Qiuli Chen, Hui Xiong, Huamei Ma, Yanhong Li, and Zhe Su
- Subjects
China ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Turner Syndrome ,Short stature ,Growth velocity ,Young Adult ,Endocrinology ,Pharmacotherapy ,Internal medicine ,Turner syndrome ,medicine ,Humans ,Prospective Studies ,Young adult ,Child ,Prospective cohort study ,Stanozolol ,Human Growth Hormone ,business.industry ,Therapeutic effect ,Estrogens ,medicine.disease ,Body Height ,Recombinant Proteins ,Treatment Outcome ,Androgens ,Female ,medicine.symptom ,business ,Follow-Up Studies ,medicine.drug - Abstract
SummaryObjective Turner syndrome (TS), which is characterized by short stature and gonadal dysfunction, is managed by pharmacotherapy. This study aimed to investigate the therapeutic effects of recombinant human growth hormone (rhGH) combined with low-dose stanozolol on the growth and final adult height (FAH) of girls with Turner syndrome (TS). Design Prospective study. Patients A total of 44 girls with TS were treated with rhGH (47·6–52·4 μg/kg/day) and low-dose stanozolol (20–35 μg/kg/day), starting at a mean age of 12·65 ± 1·99 year. The control group consisted of 22 girls with TS, who did not receive treatment. Measurements Subjects’ growth velocity (GV) was investigated. Height standard deviation score (HtSDS) was calculated relative to healthy Chinese girls (HtSDSNor) as well as untreated Chinese girls with TS (HtSDSTS). Post-treatment follow-up was performed until the subjects achieved FAH or near FAH. Results FAH was significantly higher in subjects receiving treatment compared to the untreated controls (151·42 vs 137·75 cm, P
- Published
- 2015
- Full Text
- View/download PDF
5. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China
- Author
-
Hua-mei Ma, Guo Song, Zhang Jun, LI Yan-hong, Lin Juan, Chen Qiuli, Zhe Su, Chen Hongshan, and Min-lian Du
- Subjects
Male ,China ,medicine.medical_specialty ,Outpatient Clinics, Hospital ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Population ,Urology ,Puberty, Precocious ,030209 endocrinology & metabolism ,Single Center ,Severity of Illness Index ,Cohort Studies ,Hospitals, University ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,030225 pediatrics ,Internal medicine ,Severity of illness ,medicine ,Humans ,Outpatient clinic ,Congenital adrenal hyperplasia ,Child ,education ,Growth Disorders ,Proportional Hazards Models ,Retrospective Studies ,Hydrocortisone ,education.field_of_study ,Adrenal Hyperplasia, Congenital ,business.industry ,Letrozole ,Infant, Newborn ,Infant ,Bone age ,medicine.disease ,Combined Modality Therapy ,Body Height ,Cross-Sectional Studies ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
The objective of this study was to identify variables that might interfere with reaching the near final height (NFH) in Congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency (21-OHD).A cross-sectional study of 82 (24 males and 58 females) classic (23 salt-wasting form [SW] and 59 simple-virilizing form [SV]) CAH 21-OHD patients seen in our institution between 1989 and 2015 with 10.6 (0.5~25.5) years of follow-up who reached their NFH was conducted. The variables related to NFH were explored.NFH (153.35±8.31) cm, (–1.9±1.1) SD was significantly lower than the normal population (pPatients with classic 21-OHD have blunted final height, as compared with their target height and the population norm, not-treated even worse. Careful treatment adjustments have a favorable influence on growth. Alternative treatments, such as the use of puberty inhibitors GnRHa in addition to anti-estrogen therapy letrozole can somewhat improve NFH in children with 21-OHD complicated by CPP.
- Published
- 2016
- Full Text
- View/download PDF
6. Effects of a High-Protein Diet on Insulin Resistance and Body Fat in Catch-Up Growth Rats Born Small for Gestational Age
- Author
-
Hong-Zhu Deng, Min-Lian Du, Yanhong Li, Huamei Ma, Hong Deng, and Zhe Su
- Subjects
Male ,medicine.medical_specialty ,Protein diet ,Endocrinology, Diabetes and Metabolism ,Serum insulin ,Adipose tissue ,High-protein diet ,medicine.disease_cause ,Models, Biological ,Adipose capsule of kidney ,Rats, Sprague-Dawley ,Endocrinology ,Insulin resistance ,Insulin-Secreting Cells ,Internal medicine ,Adipocytes ,medicine ,Animals ,business.industry ,medicine.disease ,Rats ,Adipose Tissue ,Animals, Newborn ,Pediatrics, Perinatology and Child Health ,Homeostatic model assessment ,Small for gestational age ,Female ,Dietary Proteins ,Insulin Resistance ,business - Abstract
Background/Aim: This study was designed to evaluate the effects of a high-protein (HP) diet on insulin resistance and body fat in catch-up growth (CUG) rats born small for gestational age (SGA). Methods: SGA rats were randomly divided into standard diet and HP diet groups. Perirenal fat weight and blood glucose, serum insulin and insulin-like growth factor-1 levels were measured at 4 and/or 8 weeks. Insulin resistance and β-cell function were evaluated by homeostatic model assessment for insulin resistance (HOMA-IR) and HOMA%. Results: The values of HOMA-IR in both CUG-SGA groups were significantly higher than those in the appropriate for gestational age (AGA) group (p < 0.01), whereas they were significantly lower in the HP diet CUG-SGA group than in the standard diet CUG-SGA group at week 8 (p < 0.01). At week 8, perirenal fat weight and adipocyte diameters were higher in both CUG-SGA groups than in the AGA group (p < 0.05), but these values were significantly lower in the HP diet CUG-SGA group than in the standard diet CUG-SGA group (p < 0.05). Conclusion: The HP diet had positive effects on the prevention of insulin resistance, which may have been caused by the reduction of body fat.
- Published
- 2012
- Full Text
- View/download PDF
7. Epidermal growth factor receptor signalling mediates growth hormone-induced growth of chondrocytes from sex hormone-inhibited adolescent rats
- Author
-
Min-Lian Du, Si-Nian Pan, Huamei Ma, Cheng-Xi Zhang, Shen-Ye Zhu, and Zhe Su
- Subjects
Pharmacology ,MAPK/ERK pathway ,medicine.medical_specialty ,biology ,Physiology ,Kinase ,Molecular biology ,Chondrocyte ,Endocrinology ,medicine.anatomical_structure ,Growth factor receptor ,Epidermal growth factor ,Physiology (medical) ,Internal medicine ,medicine ,biology.protein ,Growth factor receptor inhibitor ,Epidermal growth factor receptor ,Tyrosine kinase ,hormones, hormone substitutes, and hormone antagonists - Abstract
1. Growth hormone (GH) has been demonstrated to overcome the inappropriate deceleration of growth rate in children with central precocious puberty treated with gonadotropin-releasing hormone analogue (GnRHa). However, the underlying mechanisms remain largely unclear. In the present study, we investigated the potential involvement of the epidermal growth factor receptor (EGFR) pathway in the growth promotion by GH using in vitro cultured growth plate chondrocytes isolated from adolescent rats treated with GnRHa. 2. Chondrocytes were stimulated with GH in the presence or absence of the Janus tyrosine kinase (JAK) 2 inhibitor AG490 (1, 10 and 100 nmol/L), the EGFR kinase inhibitor AG1478 (0.1, 1 and 10 nmol/L), U0126 (an inhibitor of extracellular signal-regulated kinase (Erk) activation; 10 μmol/L) or a neutralizing antibody against epidermal growth factor (EGF Ab; 0.1, 1 and 10 μg/mL). The proliferation of chondrocytes was assessed by the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide assay and immunostaining for proliferating cell nuclear antigen (PCNA). Phosphorylation of Erk1/2 and EGFR was detected by western-blotting. Intracellular mRNA and extracellular protein levels of EGF were detected using reverse transcription-polymerase chain reaction and ELISA, respectively. 3. Growth hormone promoted the proliferation of chondrocytes, which was correlated with increased phosphorylation of Erk1/2 and EGFR and enhanced expression of EGF. Pretreatment with AG490, AG1478, U0126 or EGF Ab completely or partially inhibited the proliferation of chondrocytes and activation of Erk1/2 and EGFR. Pretreatment with AG490, AG1478, or U0126 partially inhibited the expression of EGF. 4. The findings indicate that GH promotes chondrocyte proliferation by activating EGFR signalling.
- Published
- 2011
- Full Text
- View/download PDF
8. Pubertal development timing in urban Chinese boys
- Author
-
Huamei Ma, Geli Liu, Feng Xiong, Min-lian Du, S.-K. Chen, Weiqing Wang, Xiaoping Luo, C. Zhu, Li Liu, T. Li, and Ruimin Chen
- Subjects
medicine.medical_specialty ,Spermarche ,business.industry ,Urology ,Endocrinology, Diabetes and Metabolism ,Pubarche ,Pubic hair ,medicine.anatomical_structure ,Endocrinology ,Reproductive Medicine ,Internal medicine ,medicine ,Orchidometer ,Age of onset ,business ,Body mass index ,Puberty onset ,Demography ,Sex characteristics - Abstract
We describe current pubertal development in healthy urban Chinese boys. A cross-sectional study of the pubertal development of 18,807 urban Chinese boys aged from 3.50 to 18.49years was conducted between 2003 and 2005. Testicular volume was evaluated with a Prader orchidometer. Pubic hair development was assessed according to the Tanner method. Data on spermarche were collected using the status quo method. Probit analysis was used to calculate the median age and 95% CI at different stages of testicular development, pubic hair development and spermarche. By age 9, 12.99% of the boys had a testicular volume of 4mL or greater. The median age of onset of puberty defined as the age at attainment of testicular volume of 4mL or greater was 10.55 (95% CI 10.27-10.79) years. The median age for onset of pubic hair development (PH(2) ) and spermarche was 12.78 (95%CI 12.67-12.89) years and 14.05 (95%CI 13.80-14.32) years, respectively. Pubertal onset in urban Chinese boys is earlier than currently used clinical norms but their pubic hair development occurs relatively late in comparison with the reported data from numerous other countries. There is also evidence of a secular trend towards an earlier age of spermarche since 1979 in Chinese urban boys.
- Published
- 2011
- Full Text
- View/download PDF
9. Association between height and weight catch-up growth with insulin resistance in pre-pubertal Chinese children born small for gestational age at two different ages
- Author
-
Hong-shan Chen, Hong-Zhu Deng, Zhe Su, Yue-Fang Huang, Min-Lian Du, Huamei Ma, and Yanhong Li
- Subjects
Blood Glucose ,Male ,China ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,medicine.medical_treatment ,Serum insulin ,Insulin resistance ,Pregnancy ,Risk Factors ,Internal medicine ,Homeostasis ,Humans ,Insulin ,Medicine ,Growth Charts ,Insulin-Like Growth Factor I ,Child ,reproductive and urinary physiology ,Appropriate for gestational age ,business.industry ,Body Weight ,Age Factors ,Infant, Newborn ,Infant ,medicine.disease ,Body Height ,Endocrinology ,Child, Preschool ,Infant, Small for Gestational Age ,Pediatrics, Perinatology and Child Health ,Correlation analysis ,Small for gestational age ,Female ,Insulin Resistance ,business ,Body mass index - Abstract
This study was performed to test whether children born small for gestational age (SGA) with catch-up growth (CUG) could be associated with the early development of insulin resistance and the β-cell dysfunction and to explore the impacts of height CUG and weight CUG on the insulin resistance in a Chinese population. A total of 30 children born SGA with CUG, 37 non-CUG (NCUG), and 42 born appropriate for gestational age (AGA) with normal height were recruited. Their fasting serum insulin, fasting glucose, insulin-like growth factor-1 (IGF-1) concentrations, and the homeostasis assessment model for insulin resistance (HOMA-IR) and β-cell function (HOMA%) were evaluated. The values of HOMA-IR in CUG SGA were significantly higher than that in NCUG SGA (P = 0.002) and AGA children (P = 0.036), respectively. Correlation analysis revealed that the concentrations of fasting serum insulin were positively correlated with IGF-1 (r = 0.443, P = 0.001) and Δheight standard deviation score (SDS; r = 0.500, P = 0.002) in ≤6-year-old SGA children, but only with Δweight SDS (r = 0.496, P = 0.030) in >6-year-old children. In conclusion, SGA children with CUG in height and a higher body mass index are prone to the development of insulin resistance. Higher levels of insulin were closely correlated with the postnatal height CUG in young SGA children and with the weight CUG in old children.
- Published
- 2010
- Full Text
- View/download PDF
10. Clinical evaluation of recombinant human growth hormone injection in children with growth hormone deficiency
- Author
-
Huamei Ma, Chunxiu Gong, Min-lian Du, Shui-xian Shen, Xiaoping Luo, Li Liang, Chaoying Yan, Hongwei Du, Ling Hou, Zhu-hui Zhao, G P Dong, and Yuchuan Li
- Subjects
medicine.medical_specialty ,business.industry ,Growth factor ,medicine.medical_treatment ,Bone age ,General Medicine ,medicine.disease ,Growth hormone deficiency ,Subcutaneous injection ,Endocrinology ,Blood serum ,Internal medicine ,medicine ,Bone maturation ,Thyroid function ,Adverse effect ,business - Abstract
Recombinant human growth hormone (rhGH) has been widely used in the clinical treatment of growth hormone deficiency. To simplify the injection process and increase drug compliance, application of the GH injection has become a new treatment plan in recent years. The purpose of the current study was to evaluate the efficacy and safety of rhGH injection for the treatment of growth hormone deficiency (GHD) in children in China. In a nationwide, noncomparative, prospective, randomized, open trial, 31 children with confirmed complete GHD received subcutaneous injection of rhGH at 0.25 mg/kg·wk (0.107 IU/kg·d). The injection was given daily and the total weekly amount was separated into 6–7 injections. The patients were followed up at 3-month intervals and the treatment duration was 12 months. The height (HT), annual growth velocity (GV), mean height standard deviation score (HT SDS), blood serum insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and bone maturity before and after treatment were compared, and the safety of the treatment was analyzed. The mean HT, GV, and HT SDS were increased from 109.0±14 cm, 2.7±0.9 cm/yr, and −4.62 ±1.46 at baseline to 121.8±13.4 cm, 12.9±3.3 cm/yr, and −2.47±1.86 after 12 months of treatment, respectively (P
- Published
- 2009
- Full Text
- View/download PDF
11. Postreceptor Crosstalk on PI3K/Akt between GH and Insulin in Non-Catch-Up Growth Rats Born Small for Gestational Age
- Author
-
Min-Lian Du, John W Kuluz, Ting-Ting Huang, Huamei Ma, and Yanhong Li
- Subjects
Male ,medicine.medical_specialty ,Insulin Receptor Substrate Proteins ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Gestational Age ,Phosphatidylinositol 3-Kinases ,Endocrinology ,Insulin resistance ,Pregnancy ,Internal medicine ,medicine ,Animals ,Birth Weight ,Humans ,Insulin ,Enzyme Inhibitors ,Phosphorylation ,Protein kinase B ,Growth Disorders ,PI3K/AKT/mTOR pathway ,Adaptor Proteins, Signal Transducing ,biology ,Infant, Newborn ,Tyrphostins ,medicine.disease ,Growth hormone secretion ,IRS1 ,Disease Models, Animal ,Insulin receptor ,Animals, Newborn ,Diabetes Mellitus, Type 2 ,Growth Hormone ,Infant, Small for Gestational Age ,Pediatrics, Perinatology and Child Health ,biology.protein ,Female ,Insulin Resistance ,Proto-Oncogene Proteins c-akt ,Signal Transduction - Abstract
Background/Aims: Children born small for gestational age (SGA) are at increased risk for short stature and type 2 diabetes mellitus as a result of growth hormone (GH) resistance and insulin resistance. The mechanisms of multiple hormone resistance remain unclear. This study was designed to investigate the relationship between GH resistance and insulin resistance in non-catch-up growth (NCU-SGA) rats, and how their signaling pathways are related based on their crosstalk on the insulin receptor substrate-1 phosphatidylinositol 3′-kinase (IRS-1-PI3K) pathway. Methods: NCU-SGA rat model was developed by restricting prenatal food intake in pregnant dams. Activated levels of IRS-1 and Akt in liver protein extracts were compared between NCU-SGA and age- and sex-matched controls born appropriate for gestational age rats at baseline, after insulin stimulation, and after pretreatment with AG490 (GH-JAK2 pathway inhibitor) followed by insulin stimulation. Results: GH secretion was positively related to markedly increased insulin levels in NCU-SGA rats. There was no difference of IRS-1 phosphorylation in response to insulin between two groups, however, insulin-stimulated Akt phosphorylation was attenuated in NCU-SGA rats compared to appropriate for gestational age rats. Pretreatment with AG490 restored the Akt response to insulin demonstrated by significantly increased Akt phosphorylation. Conclusion: GH plays a role in inducing insulin resistance via signaling crosstalk with insulin at the level of PI3K/Akt in NCU-SGA rats.
- Published
- 2008
- Full Text
- View/download PDF
12. Low serum adiponectin levels are associated with reduced insulin sensitivity and lipid disturbances in short children born small for gestational age
- Author
-
Min-Lian Du, Zhe Su, Yue-Fang Huang, Huamei Ma, Yanhong Li, Hong-shan Chen, and Qiuli Chen
- Subjects
Blood Glucose ,Male ,medicine.medical_specialty ,Apolipoprotein B ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Body Mass Index ,chemistry.chemical_compound ,Endocrinology ,Insulin resistance ,Internal medicine ,medicine ,Humans ,Insulin ,Insulin-Like Growth Factor I ,Child ,reproductive and urinary physiology ,Growth Disorders ,Triglycerides ,Apolipoproteins B ,biology ,medicine.diagnostic_test ,Adiponectin ,Apolipoprotein A-I ,Cholesterol ,Cholesterol, HDL ,Infant, Newborn ,nutritional and metabolic diseases ,Cholesterol, LDL ,medicine.disease ,Body Height ,Insulin-Like Growth Factor Binding Protein 1 ,chemistry ,Child, Preschool ,Infant, Small for Gestational Age ,biology.protein ,Small for gestational age ,lipids (amino acids, peptides, and proteins) ,Female ,Insulin Resistance ,Lipid profile ,Body mass index - Abstract
SummaryBackground Being born as small for gestational age (SGA) has an increased risk of developing metabolic/cardiovascular disturbances in later life. The role of adiponectin in the metabolic disturbance in SGA children remained undefined. Objective The aim of this study was to investigate the association between serum levels of adiponectin and insulin sensitivity as well as lipid profile in short children born SGA at prepubertal ages. Patients and methods Serum levels of adiponectin, fasting glucose, insulin, IGF-I, IGFBP-1, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein A-I (ApoA-I) and Apo B were measured in 30 prepubertal short children born SGA. Insulin resistance (IR) and β-cell function were assessed using the method of homeostatic model (HOMA). Data were compared to those of 30 short appropriate for gestational age (AGA) children matched for age, gender, height and body mass index, and correlation analysis was performed. Results Short SGA children had significantly higher levels of fasting insulin, HOMA-IR and HOMA-β but lower levels of adiponectin than short AGA controls. No significant differences in the level of IGFBP-1 and IGF-I were found between the two groups. Serum levels of TC, TG, Apo B and Apo B/ApoA-I ratio were significantly higher in SGA, with 33% of hypercholesteraemia and 23% of hyperglyceridaemia. Stepwise multiple regression analysis revealed that serum adiponectin level was negatively correlated with HOMA-IR and TG and was positively correlated with birthweight SDS in SGA children. Conclusions These findings suggest that low serum adiponectin levels are associated with reduced insulin sensitivity and unfavourable lipid profiles in short children born SGA at prepubertal ages.
- Published
- 2014
13. [Effect of gonadotropin-releasing hormone analog combined with stanazolol on final height in girls with idiopathic central precocious puberty and apparent decrease of linear growth]
- Author
-
Yan-hong, Li, Shun-ye, Zhu, Hua-mei, Ma, Zhe, Su, Hong-shan, Chen, Qiu-li, Chen, Yu-fen, Gu, and Min-lian, Du
- Subjects
Gonadotropin-Releasing Hormone ,Bone Development ,Child Development ,Treatment Outcome ,Human Growth Hormone ,Humans ,Puberty, Precocious ,Drug Therapy, Combination ,Female ,Child ,Body Height ,Growth Disorders ,Stanozolol - Abstract
To evaluate the effect of combined use of stanazolol (ST) on the final adult height (FAH) in girls with idiopathic central precocious puberty (ICPP) and apparently decreased linear growth during gonadotropin-releasing hormone analog (GnRHa) therapy.Sixty-three girls with ICPP and decreased velocity of growth of height (HV4 cm/yr) during GnRHa therapy were divided into 3 groups based on the following types of interventions:group 1 (n = 20), GnRHa+ST [25-30 µg/(kg·d) every 3-month followed by 3-month discontinuation], group 2 (n = 21), GnRHa+recombinant human growth hormone [rhGH, 1-1.1 U/(kg·w)], group 3 (n = 22), GnRHa alone.HV, the advancement of bone age (BA) for chronological age (CA) (ΔBA/ΔCA) and FAH were compared among groups.(1)Total duration of ST combination therapy was (12.22 ± 3.62) months, while total duration of combination of rhGH was (13.22 ± 6.80) months. (2)HV increased significantly in both group 1 [ (2.79 ± 0.60) cm/yr vs. (6.27 ± 1.98) cm/yr, P0.01] and in group 2 [(2.80 ± 0.50) cm/yr vs. (6.25 ± 1.98) cm/yr, P0.01] during combined therapy, but maintained at low levels in group 3 [(3.95 ± 1.10) cm/yr vs. (3.34 ± 0.95) cm/yr, P0.05].No significant differences of ΔBA/ΔCA were found among the three groups [0.25(0.11∼0.28), 0.22(0.15∼0.31),0.19(0.10∼0.32), P0.05]. (3)FAH was significantly higher than predicted adult height (PAH) before combined therapy, as well as higher than target height (THt) in both group 1 [(156.25 ± 2.90) cm vs. (150.78 ± 3.70) cm, P0.01, (156.25 ± 2.90) cm vs. (153.94 ± 2.62) cm, P0.01], and in group2 [ (157.33 ± 4.69) cm vs. (152.61 ± 3.92) cm, P0.01, (157.33 ± 4.69) cm vs. (154.39 ± 4.72) cm, P = 0.01].In group 3, FAH was similar to PAH [(153.88 ± 2.6) cm vs. (152.54 ± 5.86) cm, P0.05], and was less than THt [(153.88 ± 2.6) cm vs. (155.60 ± 4.52) cm, P = 0.02]. (4)In girls treated with ST, no hirsutism, clitorism or hoarse voice was recorded.No polycystic ovary syndrome was found by B-mode ultrasound.Intermittent combined use of low dose ST therapy can increase HV and thus improve FAH in girls with ICPP and apparently decreased linear growth during GnRHa therapy.
- Published
- 2014
14. [Mutation analysis for a Chinese family featuring X-linked alpha thalassemia/mental retardation syndrome]
- Author
-
Shao-bin, Lin, Hong-yu, Sun, Xin-ming, Song, Lu-ming, Chen, Min-lian, Du, and Zheng, Chen
- Subjects
Male ,X-linked Nuclear Protein ,Asian People ,alpha-Thalassemia ,Child, Preschool ,DNA Mutational Analysis ,DNA Helicases ,Mental Retardation, X-Linked ,Mutation, Missense ,Humans ,Nuclear Proteins ,Female ,Pedigree - Abstract
To identify potential mutation in a Chinese family featuring X-linked alpha thalassemia/mental retardation syndrome (ATR-X).Based on clinical symptoms and inheritance pattern, linkage analysis of X chromosome short tandem repeats (X-STR) loci was carried out to locate the candidate gene. Subsequently, sequences of exons and exon-intron boundaries of the candidate gene were amplified with polymerase chain reaction (PCR). Potential mutations were detected by direct DNA sequencing. All patients were also analyzed for the trait of thalassemia.Linkage analysis indicated the candidate gene to be ATRX. Subsequently, a homozygous missense mutation c.736CT (p.R246C) was found in exon 9 of ATRX in all of the 3 patients. And a heterozygous mutation c.736CT (p.R246C) was also identified in the patient's mother and grandmother. Similar mutations were not detected in other members of the family. Alpha thalassemia was detected in the proband and another patient, whose genotypes were determined as -α(3.7)/αα and --(sea)/αα, respectively.Missense mutation of c.736CT in ATRX gene is a mutation hotspot, and p.R246C may disturb the function of ATRX-DNMT3-DNMT3L domain (ADD), which may be responsible for the disease in this family.
- Published
- 2013
15. [A case of vaginal bleeding in toddler and standardized diagnosis and treatment of the pediatric endocrine disorders]
- Author
-
Min-lian, DU and Shu-zhong, Yao
- Subjects
Diagnosis, Differential ,Gonadotropin-Releasing Hormone ,Child, Preschool ,Vaginal Diseases ,Humans ,Puberty, Precocious ,Female ,Hysteroscopy ,Uterine Hemorrhage ,Pediatrics - Published
- 2013
16. Quantifying adherence to growth hormone treatment: the easypod™ connect observational study (ECOS)
- Author
-
Jeremy Kirk, Min-Lian Du, Dolores Rodriguez Arnao, Monia Zignani, Andrea Luczay, Sandro Loche, L. Kostalova, Jan Lebl, Jürgen Zieschang, John Vandermeulen, Martin Borkenstein, Marc Nicolino, Ho-Seong Kim, Christoph Gasteyger, Svante Norgren, and Peter Davies
- Subjects
Time on treatment ,Pediatrics ,medicine.medical_specialty ,Potential impact ,Treatment adherence ,business.industry ,Growth hormone treatment ,Recall bias ,Poster Presentation ,Emergency medicine ,medicine ,In patient ,Observational study ,Dosing ,business - Abstract
Recombinant human growth hormone (r-hGH) is indicated for pediatric patients with a variety of growth disorders. Until recently, analysis of adherence to treatment has been limited by recall bias and reliance on self-reporting. Accurate recorded data on r-hGH use can now be collected using the easypod™ auto-injector. The multinational easypod™ connect observational study (ECOS) was launched in 2010 to collect and analyze r-hGH dosing, clinical and auxological data from patients prescribed r-hGH via easypod™. Twelve countries are currently recruiting patients. The primary objective is to assess adherence in patients receiving r-hGH via easypod™. Secondary objectives include describing the impact of adherence on clinical outcomes and identifying adherence patterns. Data will be obtained from patients’ medical notes and uploaded from auto-injectors. Auxological parameters are collected, and prescribed dosing data recorded at clinic visits as per routine clinical practice. Annual adherence will be calculated (number of days the patient administered injections divided by the expected number of injection days over 1 year, as a percentage). Dose intensity (total amount of dose received divided by planned amount of dose over 1 year, as a percentage) will be analyzed. Adherence data will be correlated with clinical outcomes. An adherence pattern will also be developed based on patients’ age, sex, indication, self-injection, and time on treatment. The study will run until 2015, with yearly analyses, and will be overseen by a multinational scientific steering committee. With data from ECOS, it will be possible to accurately assess r-hGH treatment adherence in various growth disorders and explore its potential impact on growth. Ultimately, drivers of and barriers to treatment adherence will be identified, allowing appropriate support programs to be developed.
- Published
- 2013
- Full Text
- View/download PDF
17. Serum aminoterminal proctype natriuretic peptide in girls with idiopathic central precocious puberty during GNRHA treatment
- Author
-
Zhe Su, Huamei Ma, Hong-shan Chen, Yanhong Li, Min-Lian Du, and Qiu-li Chen
- Subjects
Bone growth ,medicine.medical_specialty ,biology ,medicine.drug_class ,business.industry ,Maternal and child health ,Central precocious puberty ,Endocrinology ,Internal medicine ,medicine ,Natriuretic peptide ,Osteocalcin ,biology.protein ,Oral Presentation ,Linear growth ,business ,Idiopathic central precocious puberty - Abstract
The mechanism of linear growth reduction during GnRHa treatment in central precocious puberty has not been elucidated.
- Published
- 2013
- Full Text
- View/download PDF
18. Comparative evaluation of short-term biomarker response to treatment for growth hormone deficiency in Chinese children with growth hormone deficiency born small for or appropriate for gestational age: a randomized phase IV open-label study
- Author
-
Min-lian Du, Chunxiu Gong, Wei-wei Wang, Shuixian Shen, Queena Zhou, Wenli Lu, Runming Jin, Yun Li, Xiaoping Luo, and Xuefan Gu
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Population ,IGFBP3 ,Gastroenterology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Growth hormone deficiency ,Insulin resistance ,Internal medicine ,medicine ,education ,recombinant human growth hormone ,Original Research ,education.field_of_study ,lcsh:RC648-665 ,business.industry ,Growth factor ,Insulin ,biomarker response ,insulin-like growth factor I ,medicine.disease ,Endocrinology ,Biomarker (medicine) ,Small for gestational age ,insulin-like growth factor-binding protein 3 ,business - Abstract
Objectives: To compare the response between Chinese children with growth hormone deficiency (GHD) born either small for gestational age (SGA) or appropriate for gestational age (AGA) after 4 weeks of recombinant human growth hormone (r-hGH) therapy. Methods: This was a phase IV, open-label, multicenter, interventional study (NCT01187550). Prepubertal children with GHD received open-label treatment with daily r-hGH (0.033 mg/kg) for 4 weeks. Serum levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor-binding protein 3 (IGFBP3), and metabolic markers (including fasting glucose, insulin, total cholesterol, and homeostasis model assessment of insulin resistance) were assessed at baseline and after 4 weeks of treatment, and were analyzed according to patient subgroup (SGA or AGA). Results: A total of 205 children with GHD (mean age 10.4 years; 175 AGA, 30 SGA) were included in the analysis. Mean baseline serum IGF-I and IGFBP3 standard deviation scores (SDS) across the whole patient population were lower than the population norms (mean values: -2.1 SDS for IGF-I and -1.2 SDS for IGFBP3), with no significant differences between the two patient subgroups. After 4 weeks, IGF-I and IGFBP3 levels increased by 1.0 SDS ( p < 0.001) and 0.34 SDS ( p < 0.001), respectively, but no significant differences were found between the two patient subgroups for growth-related or metabolic markers. Conclusions: For children with GHD born SGA, IGF-I and IGFBP3 are short-term biomarkers of responsiveness to treatment with growth hormone, as for children with GHD born AGA.
- Published
- 2013
19. Insulin resistance and adiponectin levels are associated with height catch-up growth in pre-pubertal Chinese individuals born small for gestational age
- Author
-
Huamei Ma, Hong Deng, Zhe Su, Yanhong Li, Min-Lian Du, Hong-Zhu Deng, and Hong-shan Chen
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Adipose tissue ,Medicine (miscellaneous) ,Catch-up growth ,lcsh:TX341-641 ,Clinical nutrition ,chemistry.chemical_compound ,Insulin resistance ,Internal medicine ,medicine ,Endocrine system ,lcsh:RC620-627 ,reproductive and urinary physiology ,Appropriate for gestational age ,Nutrition and Dietetics ,Triglyceride ,Adiponectin ,business.industry ,Research ,Small for gestational age ,medicine.disease ,female genital diseases and pregnancy complications ,lcsh:Nutritional diseases. Deficiency diseases ,Endocrinology ,chemistry ,business ,lcsh:Nutrition. Foods and food supply - Abstract
s Background and objective The study was performed to determine whether catch-up growth is associated with the development of insulin resistance and to explore serum endocrine markers associated with the metabolism of adipose tissue in a Chinese population born small for gestational age(SGA) Subjects and methods We recruited 56 children born SGA with catch-up growth and 55 born without catch-up growth, who were further grouped into groups I (with BMI catch-up) and II (without BMI catch-up) respectively, as well as 52 children born appropriate for gestational age (AGA) with normal height. Their serum fasting insulin, fasting glucose, insulin-like growth factor-1, adiponectin, IGFBP-1, triglyceride concentrations, and the homeostasis assessment model for insulin resistance (HOMA-IR) were evaluated. Results (1) The HOMA-IR values in SGA-I with catch-up growth group were significantly higher than those in SGA-II with catch-up growth, SGA-I without catch-up growth and AGA children respectively. (2) The serum adiponectin levels of individuals in the SGA-I without catch-up growth and SGA-II with catch-up growth groups were significantly lower than those from the SGA-II without catch-up growth group. There was no difference in triglyceride or IGFBP-1 levels among the groups. (3) The degree of HOMA-IR was positively correlated with age, current BMI and △height SDS in SGA children. Conclusion The development of insulin resistance and lower levels of adiponectin were closely correlated with higher BMI and the postnatal height catch-up growth in SGA children.
- Published
- 2012
20. [Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia]
- Author
-
Hui-wen, Xiao, Hua-mei, Ma, Zhe, Su, Min-lian, Du, Yan-hong, Li, Hong-shan, Chen, and Qiu-li, Chen
- Subjects
Male ,Adrenal Hyperplasia, Congenital ,Hydrocortisone ,Dehydroepiandrosterone Sulfate ,17-alpha-Hydroxyprogesterone ,Child, Preschool ,Androstenedione ,Humans ,Female ,Testosterone ,Steroid 21-Hydroxylase ,Progesterone - Abstract
To assess the utility of serum steroids measurement in monitoring the treatment of children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD).Nineteen Patients with CAH 21OHD aged (3.67±1.54) years treated with hydrocortisone and fluorocortisone replacement were followed up at an intervals of 0.33 - 1.0 years over a period of (1.47±0.7) years. At each visit, roentgenograms of the hands and wrists were taken, fasting peripheral blood were collected to test serum dehydroepiandrosterone sulfate, progesterone, 17-hydroxyprogesterone (17-OHP), androstenedione (Δ4-A), testosterone, free testosterone, estrone, and estradiol concentrations at 8 AM in the morning before the first dose of glucocorticoid. Then the patients were classified as being in "Good Control" or in "Poor Control" based on clinical criteria including signs of androgen excess, growth velocity and bone age increment at each interval. Comparisons were carried out between the serum steroid concentrations of the two groups. The receiver operating characteristic (ROC) curves were used to determine the cut-off values for diagnosing "Poor Control".Both of serum Δ4-A and 17-OHP concentrations were higher in "Poor Control" group than those in "Good Control" group [5.95 (2.23-11.2) nmol/L versus 1.05 (1.05-9.89) nmol/L, t=2.19; 13.85 (6.06-20) µg/L versus 3.67 (0.42-21.1) µg/L, t=2.17; P0.05, respectively]. The ROC curves for serum Δ4-A concentrations, serum 17-OHP concentrations, serum Δ4-A in combination with 17-OHP concentrations were constructed with areas under the ROC curves (95%CI) of 0.76 (0.62, 0.90), 0.75 (0.62, 0.88), 0.69 (0.54, 0.84), P0.05, respectively. Serum Δ4-A of 3.9 nmol/L had 0.78 of sensitivity and 0.75 of specificity in diagnosing "Poor Control". Serum 17-OHP of 7.1 µg/L has 0.67 of sensitivity and 0.71 of specificity in diagnosing "Poor Control".Each of serum 17-OHP or/and Δ4-A concentration was of significance in diagnosing "Poor Control" during the glucocorticoid replacement treatment of CAH 21OHD, with the diagnostic efficacy being serum Δ4-A concentration, serum 17-OHP concentration and serum Δ4-A in combination with 17-OHP concentration in descending order. Serum Δ4-A and 17-OHP concentrations may be used as the biochemical indicators to monitor the therapy of CAH 21OHD.
- Published
- 2012
21. [Rapid prenatal genetic diagnosis of a fetus with a high risk for Morquio A syndrome]
- Author
-
Yi-bin, Guo, Yang, Ai, Yan, Zhao, Jia, Tang, Wei-ying, Jiang, Min-lian, Du, Hua-mei, Ma, and Yan-fang, Zhong
- Subjects
Pregnancy Complications ,Base Sequence ,Pregnancy ,Risk Factors ,Prenatal Diagnosis ,Molecular Sequence Data ,Humans ,Mucopolysaccharidosis IV ,Female ,Genetic Testing ,Chondroitinsulfatases ,Pedigree - Abstract
To provide rapid and accurate prenatal genetic diagnosis for a fetus with high risk of Morquio A syndrome.Based on ascertained etiology of the proband and genotypes of the parents, particular mutations of the GALNS gene were screened at 10th gestational week with amplification refractory mutation system (ARMS), denaturing high performance liquid chromatography (DHPLC), and direct DNA sequencing.DHPLC screening has identified abnormal double peaks in the PCR products of exons 1 and 10, whilst only a single peak was detected in normal controls. Amplification of ARMS specific primers derived a specific product for the fetus's gene, whilst no similar product was detected in normal controls. Sequencing of PCR products confirmed that exons 1 and 10 of the GALNS gene from the fetus contained a heterozygous paternal c.106-111 del (p.L36-L37 del) deletion and a heterozygous maternal c.1097 TC (p.L366P) missense mutation, which resulted in a compound heterozygote status.The fetus was diagnosed with Morquio A syndrome and a genotype similar to the proband. Termination of the pregnancy was recommended. Combined ARMS, DHPLC and DNA sequencing are effective for rapid and accurate prenatal diagnosis for fetus with a high risk for Morquio A syndrome. Such methods are particularly suitable for early diagnosis when pathogenesis is clear. Furthermore, combined ARMS and DHPLC are suitable for rapid processing of large numbers of samples for the identification of new mutations.
- Published
- 2012
22. [Identification of a novel mutation of GALNS gene from a Chinese pedigree with mucopolysaccharidosis type IV A]
- Author
-
Yan, Zhao, Ya-xian, Meng, Yi-bin, Guo, Min-lian, Du, and Yang, Ai
- Subjects
Base Sequence ,Genotype ,Protein Conformation ,Molecular Sequence Data ,Infant ,Mucopolysaccharidosis IV ,Chondroitinsulfatases ,Pedigree ,Asian People ,Mutation ,Humans ,Female ,Amino Acid Sequence ,Child ,Sequence Alignment - Abstract
To study the molecular genetic mechanism of mucopolysaccharidosis type IV A(MPS IV A), and reveal the relationship between the genotype and phenotype, and provide a basis for prenatal gene diagnosis in the future.A preliminary diagnosis was made by qualitative detection of urinary glycosaminoglycans of the suspected MPS IV A proband. Then, mutation detection was performed on the proband and her family members with PCR and direct sequencing of the PCR products. After a novel c.1567T to G mutation was detected, Xsp I restriction enzyme digestion and amplification refractory mutation system (ARMS) fast specific identification were established to analyze the sequences of exon 14 in GALNS gene, including 110 randomly selected healthy controls, the proband and other pedigree members. At the same time, bioinformatic approaches for protein secondary, tertiary structure prediction were applied to identify the novel pathologic mutation.The proband's urine GAGs test was a weak positive(± ), and a c.1567T to G heterozygous termination codon mutation in exon 14 and a c.374C to T heterozygous missense mutation in exon 4 were found. The proband was compound heterozygous of the two mutations, so was her younger sister. Her mother was a carrier with only a c.1567T to G heterozygous mutation in exon 14. Her father had a heterozygous mutation of c.374C to T in exon 4. After Xsp I restriction enzyme digestion, healthy controls had three bands including 28 bp, 120 bp and 399 bp, while the proband and her mother had four bands consisting of 28 bp, 120 bp, 148 bp and 399 bp. For amplification by ARMS specific primers, it was negative for the controls, while it was positive for the proband and the carrier. The results of protein secondary and tertiary structure prediction showed that the c.1567T to G mutation located in the stop codon, resulted in stop codon (TAG) changing to glutamic acid (GAG), with the peptide chain extending 92 amino acid residues, and secondary and tertiary protein structure change, which were not found in the controls. The result of enzyme assay showed that the activity of GALNS enzyme in the affected child was 8.3 nmol/17h/mg pr, which was obviously lower than the normal value (the normal range is 41.9-92.1 nmol/17h/mg pr).These results illustrate that the c.1567 T to G is a novel pathologic mutation, which is the main cause of the disease in this family.
- Published
- 2011
23. Epidermal growth factor receptor signalling mediates growth hormone-induced growth of chondrocytes from sex hormone-inhibited adolescent rats
- Author
-
Si-Nian, Pan, Hua-Mei, Ma, Zhe, Su, Cheng-Xi, Zhang, Shen-Ye, Zhu, and Min-Lian, Du
- Subjects
Dose-Response Relationship, Drug ,Human Growth Hormone ,Puberty, Precocious ,Janus Kinase 2 ,Rats ,ErbB Receptors ,Rats, Sprague-Dawley ,Autocrine Communication ,Disease Models, Animal ,Chondrocytes ,Proliferating Cell Nuclear Antigen ,Animals ,Female ,Growth Plate ,Extracellular Signal-Regulated MAP Kinases ,Gonadal Steroid Hormones ,Cells, Cultured ,Cell Proliferation ,Signal Transduction - Abstract
1. Growth hormone (GH) has been demonstrated to overcome the inappropriate deceleration of growth rate in children with central precocious puberty treated with gonadotropin-releasing hormone analogue (GnRHa). However, the underlying mechanisms remain largely unclear. In the present study, we investigated the potential involvement of the epidermal growth factor receptor (EGFR) pathway in the growth promotion by GH using in vitro cultured growth plate chondrocytes isolated from adolescent rats treated with GnRHa. 2. Chondrocytes were stimulated with GH in the presence or absence of the Janus tyrosine kinase (JAK) 2 inhibitor AG490 (1, 10 and 100 nmol/L), the EGFR kinase inhibitor AG1478 (0.1, 1 and 10 nmol/L), U0126 (an inhibitor of extracellular signal-regulated kinase (Erk) activation; 10 μmol/L) or a neutralizing antibody against epidermal growth factor (EGF Ab; 0.1, 1 and 10 μg/mL). The proliferation of chondrocytes was assessed by the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide assay and immunostaining for proliferating cell nuclear antigen (PCNA). Phosphorylation of Erk1/2 and EGFR was detected by western-blotting. Intracellular mRNA and extracellular protein levels of EGF were detected using reverse transcription-polymerase chain reaction and ELISA, respectively. 3. Growth hormone promoted the proliferation of chondrocytes, which was correlated with increased phosphorylation of Erk1/2 and EGFR and enhanced expression of EGF. Pretreatment with AG490, AG1478, U0126 or EGF Ab completely or partially inhibited the proliferation of chondrocytes and activation of Erk1/2 and EGFR. Pretreatment with AG490, AG1478, or U0126 partially inhibited the expression of EGF. 4. The findings indicate that GH promotes chondrocyte proliferation by activating EGFR signalling.
- Published
- 2011
24. [Diagnostic value of serum levels of β-human chorionic gonadotropin (β-hcG) combined with β-hcG in cerebrospinal fluid for determining locations of germinomas in children with precocious puberty]
- Author
-
Yan-hong, Li, Zhe, Su, Hua-mei, Ma, Hong-shan, Chen, Yu-fen, Gu, and Min-lian, Du
- Subjects
Male ,Brain Neoplasms ,Case-Control Studies ,Child, Preschool ,Humans ,Puberty, Precocious ,Chorionic Gonadotropin, beta Subunit, Human ,Germinoma ,Child ,Mediastinal Neoplasms - Abstract
To study the clinical manifestations of germinoma in children with precocious puberty and to evaluate the diagnostic value of serum levels of β-human chorionic gonadotropin (β-hcG) combined with detections of β-hcG in cerebrospinal fluid (CSF).Twelve male children with germinomas confirmed by pathology from Jan. 2005 to Dec. 2009, aged from 4.2 to 10.2 years, were enrolled in this study. Patients were classified into two groups according to tumor locations: intracranial group and non-intracranial group. Levels of β-hcG in serum as well as in CSF were detected before the initiation of therapy. Age and gender matched 5 children undergoing lumbar puncture for other diseases were set as control group for the determinations of β-hcG in CSF. Levels of β-hcG and testosterone in serum and CSF were compared between intracranial group and non-intracranial group, and levels of β-hcG in CSF were compared between non-intracranial group and control group.The 12 children showed elevated serum levels of testosterone: 10.43 (1.70-254.00) µg/L, 11 children had testicular volume4 ml, while response to LHRH stimulation tests were low; 6 children had gynecomastia. Serum levels of β-hcG were elevated in both intracranial and non-intracranial group and no significant differences were found between groups 63.75 (8.50-309.50) IU/L vs. 59.00 (25.10-71.77) IU/L, P = 0.644. No correlations were found between serum levels of β-hcG and ages, tumor locations, and courses of the patients. Levels of β-hcG in CSF were significantly higher in intracranial group than that in non-intracranial group 488.99 (17.30-1048.53) IU/L vs. 1.20 (1.20-1.50) IU/L, P = 0.009. Children with non-intracranial germinomas had similar levels of β-hcG in CSF as that in control group (P = 0.571).The main clinical manifestations in boys suffered from germinoma included pseudo-precocious puberty, disproportionate testicular volume and gynecomastia. Detection of serum levels of β-hcG combined with β-hcG levels in CSF may be useful for determination of the locations of germinomas in children with precocious puberty.
- Published
- 2010
25. [Stanozolol activates the cross-talk of estrogen receptor alpha-insulin-like growth factor-1 receptor-extracellular-signal regulated kinase 1/2 in the growth plate chondrocytes of estrogen-inhibited adolescent rats in vitro]
- Author
-
Shun-ye, Zhu, Yan-hong, Li, Hua-mei, Ma, Si-nian, Pan, Hong-shan, Chen, and Min-lian, DU
- Subjects
Chondrocytes ,Mitogen-Activated Protein Kinase 3 ,Androgens ,Estrogen Receptor alpha ,Animals ,Female ,Growth Plate ,Receptor Cross-Talk ,Cells, Cultured ,Stanozolol ,Rats ,Receptor, IGF Type 1 ,Signal Transduction - Abstract
To investigate the effects and the mechanisms of stanozolol (ST) on the proliferation, maturation and differentiation of in vitro cultured growth plate chondrocyte isolated from gonadotropin releasing hormone analogue (GnRHa)-treated adolescent rats, to study if ST mediates the proliferation of chondrocytes via the estrogen receptor alpha (ERalpha), androgen receptor (AR) and/or insulin-like growth factor-1 receptor (IGF-1R) and interactions of the two receptor and IGF-1R receptor signaling pathway, to investigate the mechanism of the biological effects in ST promoting bone growth/maturity at molecular level.The rats were weaned at the end of 3 weeks and intramuscular injection of triptorelin of GnRHa preparations, qow x 2 was started. The rats were sacrificed at the end of 7 weeks, and then the tibiae growth plates were taken out with sterile procedure. The chondrocytes were obtained by two-time enzyme digestion method, and the experiments were carried out with the primary chondrocytes. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) and Western blot analysis were applied.The results of PCNA demonstrated that stanozolol enhanced the proliferation of the chondrocytes, time-course studies showed that the proliferation were maximally stimulated by stanozolol after 2 days of incubation and decreased again after longer periods of incubation. The expression of p-ERalpha, p-IGF-1R and p-extracellular-signal regulated kinase 1/2 (ERK1/2) increased with the incubation period of ST treatment, and reached the peak value at a certain time, and then gradually decreased. The expression of p-ERalpha, p-IGF-1R and p-ERK1/2 increased with the elevation of ST concentration, and reached the peak value at 10(-9) - 10(-8) mol/L, then gradually decreased. ST induced-p-ERalpha expression was partially blocked by ERalpha and mitogen-activated protein kinase kinase inhibitors. ST induced-p-IGF-1R expression was partially blocked by ERalpha and IGF-1R inhibitors. ST induced-p-ERK1/2 expression was partially blocked by mitogen-activated protein kinase kinase and IGF-1R inhibitors.As an androgen derivation, ST exerts its biological effects of promoting proliferation of the long bone growth plate chondrocytes via activating the classic ERalpha receptor pathway and mitogen-activated protein kinase pathway, and at the same time, by activation of IGF-1R. Both IGF-1R and ERalpha can promote "cross-talk" of two systems' receptor signal through mitogen-activated protein kinase signal pathway.
- Published
- 2009
26. [How to grasp the core issues for diagnosis and treatment of central precocious puberty]
- Author
-
Min-lian, Du
- Subjects
Central Nervous System Diseases ,Practice Guidelines as Topic ,Humans ,Puberty, Precocious - Published
- 2009
27. [Longitudinal study of the pattern of pubertal development in Cantonese schoolgirls]
- Author
-
Yan-hong, Li, Hua-mei, Ma, Hong-shan, Chen, Zhe, Su, Yu-fen, Gu, and Min-lian, Du
- Subjects
China ,Adolescent ,Body Weight ,Puberty ,Humans ,Female ,Longitudinal Studies ,Sexual Maturation ,Adolescent Development ,Child ,Students ,Body Height - Abstract
To investigate the pattern of pubertal development in healthy Cantonese schoolgirls.From 1992 to 2001, 311 normal Cantonese schoolgirls, ages from 6.25 to 8.83 yrs (7.24 +/- 0.38) at baseline, were followed up until they reached their final adult height (age 15.72 +/- 0.84 yrs, n = 238). Annual physical examinations including height and weight measurement were performed. From the 3rd visit, pubertal maturations (breast and pubic hair development) were also assessed annually until they were 14.5 years. Age of menarche was recorded.(1) Median age at the entry of puberty (age at reaching B2) was 9.83 years (9.33-10.33). Median age at initiation of pubic hair development (PH2) was 10.67 (9.92-11.38) years. Menarche occurred at (12.35 +/- 1.30) years. The age at reaching B2, age at reaching PH2 and age of menarche were all later than that observed in the cross-section study performed in 2003, Guangzhou, China. Peak height velocity (PHV) was reached at (10.52 +/- 1.07) years, 1.00 (0.50-1.50) years after B2 was reached. Interval between "age at onset of breast development" and "age at menarche" was 2.92 (2.08-3.67) years. Duration of pubertal growth (defined as the time from age at B2 to age at which adult height was attained) was (4.80 +/- 0.85) years. (2) Average final adult height (FAH) was (158.74 +/- 5.74) cm. As compared with the cross-section studies held in Guangzhou, China, the FAH in our study was higher than that observed in 1985 but was lower than that observed in 2003. (3) Multiple linear regression analyses showed that the age reaching B2 was an independent factor associated with the age of menarche. (4) Durations of breast stages, interval between B2 and menarche and duration of pubertal growth were similar to that reported in the longitudinal studies in the United Kingdom (1969), Senegal (1995-2000), the United States (1986-1996).In healthy Cantonese schoolgirls, the timing of sexual maturation was in a trend of decline in the past 20 years, however it may have no significant impacts on the tempo of pubertal development and FAH.
- Published
- 2009
28. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial]
- Author
-
Ling, Hou, Xiao-ping, Luo, Min-lian, Du, Hua-mei, Ma, Chun-xiu, Gong, Yu-chuan, Li, Shui-xian, Shen, Zhu-hui, Zhao, Li, Liang, Guan-ping, Dong, Chao-ying, Yan, and Hong-wei, Du
- Subjects
Male ,China ,Insulin-Like Growth Factor Binding Protein 3 ,Human Growth Hormone ,Humans ,Female ,Prospective Studies ,Insulin-Like Growth Factor I ,Child ,Dwarfism, Pituitary ,Growth Disorders ,Recombinant Proteins - Abstract
Human growth hormone (hGH) is an essential therapeutic drug for the treatment of growth hormone (GH) deficiency (GHD). However, the process of dissolving hGH of the powder form is complicated and potentially hazardous. In the present study, we evaluated the efficacy and safety of preparation in the replacement therapy for children with GH deficiency.A 12-month randomized, open-label, multicenter trial was conducted in 31 previously untreated children with growth failure secondary to GH deficiency [20 boys and 11 girls, mean age (10.5 +/- 4.1) years]. An recombined human growth hormone (rhGH) solution (Iintropin AQ) was given via subcutaneous injection daily in every evening at a weekly dose of 0.25 mg/kg. The patients were followed up at 3, 6, 9, and 12 months of the treatment, and the course of treatment was 12 months. Body height was measured 3-monthly and height velocity (HV) and mean height standard deviation score (HT SDS) were calculated. Serum Insulin-like growth factor I (IGF-1), Insulin-like growth factor binding protein 3 (IGFBP-3), GH antibodies and safety parameters were assessed at the baseline and at 3-month intervals. Bone age (BA) was assessed at the baseline and the rate of skeletal maturation (DeltaBA/DeltaCA) was calculated after 6 and 12 months of rhGH treatment by a central bone age reader. Moreover, the safety of rhGH solution treatment was assessed.After 12 months of liquid rhGH therapy, growth parameters were significantly increased over baseline. (1) The mean (+/- SD) height increment DeltaHT (cm) was 4.0 +/- 1.3, 7.0 +/- 2.0, 10.3 +/- 2.6 and 12.9 +/- 3.3 after 3, 6, 9, and 12 months of treatment, respectively (P0.01), which indicated linear growth after treatment. The GV (cm/years) was 2.7 +/- 0.9 before treatment and increased to 16.0 +/- 5.1, 14.1 +/- 4.0, 13.7 +/- 3.5, and 12.9 +/- 3.3 after treatment, suggesting that catch-up growth was significant after treatment as compared to the pre-treatment status (P0.01). Accordingly, post-treatment catch-up growth was obvious, significant differences were observed in HT SDS, which was -4.62 +/- 1.46 at the onset of therapy and increased significantly after the treatment to -3.80 +/- 1.53, -3.28 +/- 1.60, -2.86 +/- 1.75 and -2.47 +/- 1.86, respectively (P0.01). The height difference between GH deficient children and unimpaired children of the same age and gender gradually decreased after treatment, which was significantly different from that seen before treatment (P0.01). (2) The levels of serum IGF-1 and IGFBP-3 were increased comparably for the treatment. IGF-1 level (microg/L) was 41 +/- 64 at baseline and increased to 179 +/- 155, 202 +/- 141, 156 +/- 155 and 159 +/- 167 after 3, 6, 9, 12 months of treatment. IGFBP-3 level (mg/L) was 1540 +/- 1325 at baseline, and increased to 3891 +/- 1815, 4051 +/- 1308, 3408 +/- 1435 and 3533 +/- 1413, respectively, suggesting that with the increases in height, IGF-1, and IGFBP-3 were significantly activated to relatively high levels by the medication and reached peak values between 3 and 6 months of treatment. The levels of IGF-1 and IGFBP-3 were significantly different before and after treatment (P0.01). The IGF-1/IGFBP-3 molar ratio significantly increased during GH therapy (0.143 +/- 0.013 pre-therapy up to 0.240 +/- 0.055 post-therapy, P0.01). The IGF-1/IGFBP-3 molar ratio tended to stabilize after 3-month GH therapy. (3) The bone age assessment carried out 6 and 12 months after treatment showed that the bone maturity (DeltaBA/DeltaCA) was 1.01 +/- 0.57 and 1.07 +/- 0.75, respectively, suggesting that there was no speed-up development in the bone age. No severe adverse events were observed during the trial and the most frequent accompanying event was mild hypothyroidism.rhGH solution (Iintropin AQ) is a safe and effective preparation in the replacement therapy for children with GH deficiency.
- Published
- 2009
29. [Insulin resistance and growth]
- Author
-
Min-lian, DU
- Subjects
Child Development ,Child, Preschool ,Infant, Newborn ,Humans ,Infant ,Growth ,Insulin Resistance - Published
- 2008
30. [Establishment and validation of predictive model of short term responses to recombinant human growth hormone treatment in prepubertal short stature children with various growth hormone secretary statuses]
- Author
-
Zhe, Su, Yan-hong, Li, Hua-mei, Ma, Hong-shan, Chen, Min-lian, DU, and Yu-fen, Gu
- Subjects
Male ,Models, Statistical ,Adolescent ,Human Growth Hormone ,Body Height ,Treatment Outcome ,Child, Preschool ,Growth Hormone ,Humans ,Female ,Prospective Studies ,Child ,Growth Disorders ,Retrospective Studies - Abstract
It has been proved that to analyze the factors that determine responsiveness to rhGH and to develop growth prediction models can help doctors to individualize the treatment and maximize the effect.To set up and validate the predictive models of growth responses to rhGH treatment in the first year in prepubertal short stature children with various GH secretary statuses.Growth responses to rhGH treatment in the first year, height velocities (HV) and increases in height SDS (DeltaHtSDS), in 62 prepubertal short stature children with various GH secretary statuses were analyzed retrospectively. There were 27 patients with complete growth hormone deficiency (cGHD), 23 with partial GHD (pGHD) and 12 with idiopathic short stature (ISS) in the model group. According to the peak GH value in GH provocative test, the group of pGHD was divided into pGHD-1 (5 - 6.9 microg/L, 12 patients) and pGHD-2 (7 - 9.9 microg/L, 11 patients). All the cases in model group were used for setting up Model-total and the cases of growth hormone deficiency for Model-GHD. Predictive models, including Model-GHD and Model-total, to HV and DeltaHtSDS were set up by the way of multiple regression analysis, based on the results of simple correlation analysis. Other 14 children were included according to the same criteria with the model group, the validation group. The validation group was analyzed prospectively. The actual growth responses were compared with the predicted values calculated by different models so that the predictive models could be validated.The simple correlation analysis showed that HV and DeltaHtSDS in the first year were negatively correlated with the same group factors at baseline: chronological age, bone age, height SDS, differences between the height SDS and the target height SDS, peak value in GH provocative test and IGF-1SDS. All the 4 predictive models were found to be significant at a level of P0.05, R(2) ranged from 0.244 to 0.519. The two models predicted HV and Model-GHD for DeltaHtSDS were proved to be validated. The observed and predicted responses positively and significantly correlated with each other, r value ranged from 0.753 to 0.996. And there was no significant difference between them when tested by paired t test.The availability of the predictive model will help to individualize the growth hormone treatment in prepubertal short stature children with various growth hormone secretary status.
- Published
- 2008
31. An analysis of predictive factors for the conversion from premature thelarche into complete central precocious puberty
- Author
-
Shun-Ye, Zhu, Min-Lian, Du, and Ting-Ting, Huang
- Subjects
Risk Factors ,Age Determination by Skeleton ,Child, Preschool ,Humans ,Puberty, Precocious ,Female ,Breast ,Child ,Prognosis ,Follow-Up Studies - Abstract
To determine the predictive factors for the conversion of premature thelarche (PT) into complete central precocious puberty (CCPP) in girls.Prospective.One hundred and fifty-one girls with PT referred consecutively for evaluation of clinical, laboratory, and ultrasound data.Twenty-one and a half percent of girls with PT converted into CCPP at a chronological age of 7.1 +/- 0.7 years and bone age of 9.0 +/- 1.1 years. Using logistic regression analysis, longitudinal diameter of uterus (OR = 1.215), Tanner breast stage at the time of first physical examination (OR = 3.334) and regression of breast development (OR = 3.921) were the most significant variables predicting the conversion from PT into CCPP. Compared with the non-converted group, the converted groups had larger breast size at the time of diagnosis (z = 2.077, p = 0.038). A total of 69.5% (105/151) of patients experienced complete regression of breast development, 13.2% (14/105) of whom converted into CCPP; 21.5% (31/151) of patients had recurrent breast development, 32.3% (10/31) of whom converted into CCPP; 10% (15/151) of patients had constant breast development, 56.7% (7/15) of whom converted into CCPP, with the highest rate among the three breast development categories (chi2 = 12.23, p = 0.002).PT is not often a self-limited condition and may sometimes convert into CCPP. The predictive factors for conversion were related to estrogen exposure including longitudinal diameter of the uterus, Tanner breast stage at the first consultation and the regressive categories of breast development.
- Published
- 2008
32. [Correlation between growth hormone/insulin-like growth factor-1 resistance and insulin resistance in non catch-up growth rats born small for gestational age]
- Author
-
Ting-Ting, Huang, Min-Lian, Du, Hua-Mei, Ma, Zhe, Su, and Yu-Fen, Gu
- Subjects
Blood Glucose ,Male ,Time Factors ,Morpholines ,Body Weight ,Gestational Age ,Rats ,Rats, Sprague-Dawley ,Animals, Newborn ,Chromones ,Pregnancy ,Growth Hormone ,Animals ,Birth Weight ,Insulin ,Female ,Insulin Resistance ,Insulin-Like Growth Factor I ,Phosphoinositide-3 Kinase Inhibitors - Abstract
To investigate the post-receptor signaling mechanism responsible for insulin resistance-induced growth hormone (GH) resistance in non-catch-up (NCU) growth rats born small for gestational age (SGA).Twenty pregnant female SD rats were fed with restricted food (40% of normal intake, 9 g/d) throughout the pregnancy so as to develop NCU-SGA rats. The rats with their length and body weightor = -2SD were out into the NCU-SGA group, and those with their length and body weight-2SD were out into the catch-up (CU) growth group. Rats born to normally-fed pregnant rats were set as normal control (control Group, C Group, n = 17). The body weight and length were measured every 2 weeks. At the age of 4 weeks, 24 h urine was collected to measure the urine GH (U-GH). Then blood samples were collected to measure the serum insulin-like growth factor-1 (IGF-1), fasting insulin (FINS), and glucose levels, and the liver was taken out to detect the expression of STAT5 signal. Twelve 3-week NCU-SGA rats were divided into 2 equal groups: P13K blocking group, undergoing intraperitoneal injection of LY294002, blocker of P13K twice every 3 days, and solvent control group, undergoing intraperitoneal injection of DMSO. At the age of 4 weeks, blood samples were collected and then the liver was taken out to detect the IGF-1 mRNA and STAT5 signal.(1) The body weight and length at birth of the NCU-SGA group were (4.4 +/- 0.5) g and (4.5 +/- 0.2) cm, both significantly lower than those of Group C [(6.8 +/- 0.6) g and (5.3 +/- 0.2) cm respectively], and the body weight and length at 4 weeks of age of the NCU-SGA group were (63 +/- 12) g and (13.2 +/- 1.0) cm respectively, both significantly lower than those of the C group [(88 +/- 12) g and (15.3 +/- 0.5) cm respectively, all P0.01]. The serum IGF-1 level, IGF-1 mRNA expression, and total and phosphate STAT5 level in liver of the NCU-SGA group were (248 +/- 58) ng/ml, (6.1 +/- 0.3) copies, and (61 +/- 22)% respectively, all significantly lower than those of the C group [(383 +/- 62) ng/ml, (6.6 +/- 0.4) copies, and (91 +/- 29)%, all P0.01]. There was no statistic difference in 24 h U-GH between the NCU-SGA and C groups (P0.05). The FINS and glucose level of the NCU-SGA group were (24.7 +/- 9.6) mU/ml and (5.4 +/- 0.3) mmol/L respectively, both significantly higher than those of the C group [(9.8 +/- 2.8) mU/ml and (4.5 +/- 1.7) mmol/L respectively, both P0.05]. The level of 24 h U-GH was positively correlated with FINS (r = 0.680, P = 0.000). No correlation was found between IGF-1 and fasting insulin level. (2) After the PI3K pathway was chronically blocked, the NCU-SGA rats lost weight and developed a more severe insulin resistance, decreased serum IGF-1 level and the IGF-1 mRNA expression level of the PI3K inhibitor group were (218 +/- 60) ng/ml and (6.1 +/- 0.3) copies respectively, both significantly lower than those of the solvent control group [(286 +/- 45) ng/ml and (6.3 +/- 0.3) copies, both P0.05]. No statistically significant difference in total and phosphate STAT5 levels in liver between the P13K blocker and solvent groups.GH resistance is closely associated with insulin resistance in the NCU-SGA rats. GH resistance-induced failure of catch-up growth is related to the impairment of JAK2-STAT5 pathway. Insulin resistance exacerbates growth axis resistance and growth retardation in NCU-SGA rats via a non-STAT5 dependent pathway.
- Published
- 2007
33. Molecular genetic diagnostics of Prader-Willi Syndrome: a validation of linkage analysis for the Chinese population
- Author
-
Haiyun Wei, Min-lian Du, Xin-ming Song, Shu Meng, Huamei Ma, Haifei Li, Hong-lei Duan, Zheng Chen, Qing Wenren, Hongyi Li, and Hui Zheng
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,Genetic Linkage ,Genetic counseling ,Mothers ,Uniparental Heterodisomy ,Biology ,Bioinformatics ,Polymerase Chain Reaction ,Chromosome 15 ,Fathers ,Genotype-phenotype distinction ,Chromosome (genetic algorithm) ,Asian People ,Genetic linkage ,Genetics ,medicine ,Humans ,Child ,Molecular Biology ,Chromosome Aberrations ,Chromosomes, Human, Pair 15 ,Genetic disorder ,nutritional and metabolic diseases ,Uniparental Disomy ,medicine.disease ,Uniparental disomy ,nervous system diseases ,Chromosome Banding ,Child, Preschool ,Chromosome Deletion ,Prader-Willi Syndrome - Abstract
Prader-Willi Syndrome (PWS) is a genetic disorder that is difficult to detect, particularly at an early age. PWS is caused by disruption of normal, epigenetically controlled gene function in the chromosome 15q11-q13 region. Clinical symptoms are difficult to diagnose in infants and only become clearer at later ages as the patients develop hyperphagia and morbid obesity. Molecular genetic tests are able to definitively diagnose PWS and allow early diagnosis of the syndrome. High resolution cytogenetic testing, methylation-specific PCR (MS-PCR), and linkage analysis are routinely used to diagnose PWS. To establish a linkage analysis method for Chinese patients, this study identified a useful set of STR markers in the typical PWS deletion and adjacent area, for linkage analysis in two Chinese families with PWS offspring. Using this method, the authors confirmed that one patient had a paternal deletion in chromosome 15q11-q13 and the other patient had maternal uniparental heterodisomy of chromosome 15. MS-PCR and high resolution chromosome G-banding also confirmed this diagnosis. This linkage analysis method can detect both deletion and uniparental disomy, thus providing valuable information for genetic counseling and the opportunity to analyze the relationship between the genotype and phenotype of PWS.
- Published
- 2007
34. [Factors determining growth response in recombinant growth hormone treatment of growth hormone deficient children]
- Author
-
Si-nian, Pan, Min-lian, Du, and Hong-shan, Chen
- Subjects
Male ,Time Factors ,Adolescent ,Human Growth Hormone ,Age Factors ,Body Height ,Drug Administration Schedule ,Recombinant Proteins ,Body Mass Index ,Treatment Outcome ,Child, Preschool ,Humans ,Female ,Child ,Growth Disorders ,Follow-Up Studies - Published
- 2006
35. [Diagnosis of hereditary tyrosinemia type I: clinical study of ten patients]
- Author
-
Xiao-yu, Li, Min-lian, DU, and Si-qi, Zhuang
- Subjects
Male ,Methionine ,Tyrosinemias ,Child, Preschool ,Humans ,Infant ,Tyrosine ,Female ,Tyrosine Transaminase - Published
- 2006
36. [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder]
- Author
-
Hong-yu, Zhang, Min-lian, Du, Si-qi, Zhuang, and Mei-na, Liu
- Subjects
Male ,Child Development ,Attention Deficit Disorder with Hyperactivity ,Case-Control Studies ,Body Weight ,Methylphenidate ,Humans ,Regression Analysis ,Central Nervous System Stimulants ,Female ,Child ,Body Height - Abstract
To determine whether long-term treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate influences the growth in height and weight of children.Analyses were performed on 146 school age children (126 boys) diagnosed as ADHD and treated with methylphenidate [0.27-0.64 mg/(kg.day)] for methylphenidate group and 29 children with ADHD who did not receive any medication for ADHD (controls). These children were followed-up for 2-4 years. Changes in height and weight after long-term treatment with methylphenidate were recorded and the factors affecting growth of height, weight, and height velocity were analyzed.The change of difference between patients' height and mean height in methylphenidate group and controls was (-1.86 +/- 0.82) cm (paired t test, t = 27.335, P0.001) and (-0.26 +/- 0.51) cm (P0.05), respectively; the change of height standard deviation score (SDS) in methylphenidate group and controls was -0.14 +/- 0.23 SD (paired t test, t = 7.326, P0.001) and +0.05 +/- 0.10 SD (P0.05), respectively. When the height change and height SDS change in methylphenidate group and controls were compared by using independent-samples T-test, the t value was -10.078 and -4.262 respectively, P for both was0.001. Both of bivariate correlation analysis and stepwise multiple-regression analysis indicated that the duration of treatment contributed significantly to the variance in change of height (P0.001); but age, sex, DSM-IV type, NJ22 degree and dose of methylphenidate did not contribute significantly to the variance of height. The mean height velocity from 1st to 4th year was 4.28 cm/year, 4.90 cm/year, 4.98 cm/year and 4.95 cm/year, respectively. With Friedman test, Chi-square = 253.673, P0.001. The change of difference of patients' weight to weight for height after methylphenidate was (-0.14 +/- 1.25) kg (paired t test, t = 1.326, P0.05).Small but significant deceleration of height velocity is the identified long-term side effect of methylphenidate, the magnitude of height deficit is related to duration of treatment. The height velocity was significantly attenuated in the first year. Methylphenidate had no significant influence on weight.
- Published
- 2005
37. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
- Author
-
Xiaoping Luo, Ling Hou, Li Liang, Guanping Dong, Shuixian Shen, Zhuhui Zhao, Chun Xiu Gong, Yuchuan Li, Min-lian Du, Zhe Su, Hongwei Du, and Chaoying Yan
- Abstract
Objective: We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). Design: Phase II and III, multicenter, open-label, randomized controlled trials. Methods: 108 and 343 children with treatment-naive GHD from 6 hospitals in China were enrolled in the phase II and III studies respectively. Patients in the phase II study were randomized 1:1:1 to weekly Jintrolong (0.1 mg/kg/week PEG- rhGH complex), weekly Jintrolong (0.2 mg/kg/week PEG-rhGH complex) or daily rhGH (0.25 mg/kg/week) for 25 weeks. Patients in the phase III study were randomized in a 2:1 ratio to weekly Jintrolong (0.2 mg/kg/week) or daily rhGH (0.25 mg/kg/week) for 25 weeks. The primary endpoint for both studies was height velocity (HV) increase at the end of treatment. Other growth-related parameters, safety and compliance were also monitored. Results: The phase II study established the preliminary efficacy, safety and recommended dose of Jintrolong PEG-rhGH. In the phase III study, we demonstrated significantly greater HV increases in patients receiving Jintrolong treatment (from 2.26 ± 0.87 cm/year to 13.41 ± 3.72 cm/year) vs daily rhGH (from 2.25 ± 0.82 cm/year to 12.55 ± 2.99 cm/year) at the end of treatment (P < 0.05). Additionally, significantly greater improvement in the height standard deviation scores was associated with Jintrolong throughout the treatment (P < 0.05). Adverse event rates and treatment compliance were comparable between the two groups. Conclusion: Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
38. [Expression of tumor necrosis factor alpha mRNA in adipose cell of intrauterine growth retarded rats and its relation to insulin resistance]
- Author
-
Ting-Ting, Huang, Xiao-Shan, Qiu, Min-Lian, DU, Zhen-Yu, Shen, Zhi-Yong, Ke, and Feng, Lai
- Subjects
Random Allocation ,Fetal Growth Retardation ,Adipose Tissue ,Pregnancy ,Tumor Necrosis Factor-alpha ,Animals ,Nutritional Status ,Female ,Insulin Resistance ,Diet ,Rats - Abstract
To investigate the association between the expression of turnor necrosis factor alpha (TNF-alpha) mRNA in fat tissue of intrauterine growth retarded (IUGR) rats and insulin resistance, and the long-term effects of early different nutritional diet.The IUGR rat model was established by food restriction of pregnant rats. A total of 32 newborn IUGR rats were randomly divided into 4 groups: IUGR model (S/N) group, IUGR high caloric diet (A) group, IUGR high caloric and high protein diet (B) group, IUGR high protein diet (C) group. Only the mother rats were given those different diets individually, and all IUGR newborn pups were lactated for 3 weeks. From the beginning of the 4(th) week, all IUGR pups were weaned and fed with normal diet till the end of the experiment. Eight normal birth weight newborn rats were used as the control group fed with the normal diet. Weight, perirenal fat weight, fasting glucose and insulin concentration and quantified TNF-alpha mRNA expression in adipose cell were measured at the 48(th) week. The insulin sensitive index (ISI) and the relation index between TNF-alpha mRNA and fat weight, fat weight/body weight (fw/bw) ratio and ISI were calculated.ISI of IUGR model group, IUGR A and B groups was lower than normal control group, while perirenal fat weight, fw/bw and the expression of TNF-alpha mRNA in adipose cells were all significantly higher (P0.05 or 0.01). There were no significant differences in these indexes between IUGR C group and normal control groups (P0.05). A positive correlation was found between TNF-alpha mRNA and fat weight and fw/bw (r(1) = 0.755, r(2) = 0.782, P = 0.000). Significant inverse associations between ISI and TNF-alpha mRNA (r = -0.556, P = 0.000) and fw/bw (r = -0.513, P = 0.02) were also found.The occurrence of insulin resistance in IUGR rats is possibly associated with central obesity and accumulation of the abdominal fat and adipose cell over-expression of TNF-alpha. The adipose TNF-alpha may be an important pathogenic factor of insulin resistance of IUGR. High protein diet is a reasonable nutritional intervention. Because it promotes the skeleton muscle catch-up growth but not fat catch-up growth, it can avoid the occurrence of central obesity and insulin resistance in IUGR rats.
- Published
- 2005
39. [One case with pineal germinoma]
- Author
-
Shu-Li, Chen, Min-Lian, Du, Ruo-Xin, Li, Quan, Yuan, Jianxiang, Liao, Li, Chen, Wei, Chen, Min, Lei, Huiying, Tang, and Chengrong, Li
- Subjects
Brain Neoplasms ,Humans ,Germinoma ,Pineal Gland - Published
- 2004
40. Associations between Serum Apelin-12 Levels and Obesity-Related Markers in Chinese Children
- Author
-
Huamei Ma, Yanhong Li, Zhe Su, Qiuli Chen, Min-Lian Du, Hong-Jun Ba, and Hong-shan Chen
- Subjects
Blood Glucose ,Male ,Anatomy and Physiology ,medicine.medical_treatment ,lcsh:Medicine ,Biochemistry ,Pediatrics ,Body Mass Index ,chemistry.chemical_compound ,Pathology ,Insulin ,Child ,lcsh:Science ,Multidisciplinary ,Anthropometry ,Lipids ,Apelin ,Medicine ,Intercellular Signaling Peptides and Proteins ,Female ,Research Article ,medicine.medical_specialty ,Endocrine System ,Biology ,Statistics, Nonparametric ,Childhood obesity ,Sex Factors ,Insulin resistance ,Adolescent Medicine ,Asian People ,Diagnostic Medicine ,Internal medicine ,medicine ,Humans ,Obesity ,Nutrition ,Plasma Proteins ,Endocrine Physiology ,Cholesterol ,lcsh:R ,Proteins ,Lipid Metabolism ,medicine.disease ,Endocrinology ,chemistry ,lcsh:Q ,Insulin Resistance ,Body mass index ,Biomarkers ,General Pathology - Abstract
Objective To investigate possible correlations between apelin-12 levels and obesity in children in China and associations between apelin-12 and obesity-related markers, including lipids, insulin sensitivity and insulin resistance index (HOMA-IR). Methods Forty-eight obese and forty non-obese age- and gender-matched Chinese children were enrolled between June 2008 and June 2009. Mean age was 10.42±2.03 and 10.86±2.23 years in obesity and control groups, respectively. Main outcome measures were apelin-12, BMI, lipids, glucose and insulin. HOMA-IR was calculated for all subjects. Results All obesity group subjects had significantly higher total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), insulin levels and HOMA-IR (all P
- Published
- 2014
- Full Text
- View/download PDF
41. Insulin resistance and adiponectin levels are associated with height catch-up growth in pre-pubertal Chinese individuals born small for gestational age.
- Author
-
Hong-Zhu Deng, Hong Deng, Zhe Su, Yan-Hong Li, Hua-Mei Ma, Hong-Shan Chen, and Min-Lian Du
- Subjects
ADIPOSE tissues ,ANALYSIS of variance ,BIRTH size ,BLOOD sugar ,STATISTICAL correlation ,FISHER exact test ,INSULIN ,INSULIN resistance ,RESEARCH funding ,SOMATOMEDIN ,STATISTICS ,STATURE ,T-test (Statistics) ,TRIGLYCERIDES ,BODY mass index ,ADIPONECTIN ,DESCRIPTIVE statistics ,CHILDREN - Abstract
Background and objective: The study was performed to determine whether catch-up growth is associated with the development of insulin resistance and to explore serum endocrine markers associated with the metabolism of adipose tissue in a Chinese population born small for gestational age(SGA) Subjects and methods: We recruited 56 children born SGA with catch-up growth and 55 born without catch-up growth, who were further grouped into groups I (with BMI catch-up) and II (without BMI catch-up) respectively, as well as 52 children born appropriate for gestational age (AGA) with normal height. Their serum fasting insulin, fasting glucose, insulin-like growth factor-1, adiponectin, IGFBP-1, triglyceride concentrations, and the homeostasis assessment model for insulin resistance (HOMA-IR) were evaluated. Results: (1) The HOMA-IR values in SGA-I with catch-up growth group were significantly higher than those in SGA-II with catch-up growth, SGA-I without catch-up growth and AGA children respectively. (2) The serum adiponectin levels of individuals in the SGA-I without catch-up growth and SGA-II with catch-up growth groups were significantly lower than those from the SGA-II without catch-up growth group. There was no difference in triglyceride or IGFBP-1 levels among the groups. (3) The degree of HOMA-IR was positively correlated with age, current BMI and ?height SDS in SGA children. Conclusion: The development of insulin resistance and lower levels of adiponectin were closely correlated with higher BMI and the postnatal height catch-up growth in SGA children. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
42. Stanozolol regulates proliferation of growth plate chondrocytes via activation of ER a in GnRHa-treated adolescent rats.
- Author
-
Shun-Ye Zhu, Yan-Hong Li, Hua-Mei Ma, Ting-Ting Huang, Hai-Bin Luo, Juan Dou, and Min-Lian Du
- Abstract
Improving the fi nal adult height is one of the most important aims for treatment of central precocious puberty. Stanozolol (ST) is a synthetic derivative of androgen. In this study, we investigated the effects and the mechanisms of ST on the proliferation of growth plate chondrocytes isolated from adolescent rats treated with gonadotropin-releasing hormone analogue (GnRHa). Treatment with ST resulted in time- and concentration-dependent effects on proliferation as determined by MTT and proliferating cell nuclear antigen (PCNA) assays. Western blotting showed that ST increased the phosphorylation level of the estrogen receptor a (ER a ), but not the androgen receptor (AR). Pharmacological inhibition of ER a and mitogen-activated protein kinase (MAPK) attenuated the effects of ST on the proliferation of growth plate chondrocytes. A molecular dynamics simulation showed hydrophobic interactions between ST and ER a . These results suggested that ER a, but not AR, partially mediates the ST-driven proliferation of growth plate chondrocytes, and that multiple pathways may be involved in the mechanism of action of ST. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
43. Association between height and weight catch-up growth with insulin resistance in pre-pubertal Chinese children born small for gestational age at two different ages.
- Author
-
Hong-Zhu Deng, Yan-Hong Li, Zhe Su, Hua-Mei Ma, Yue-Fang Huang, Hong-Shan Chen, and Min-Lian Du
- Subjects
LOW birth weight ,CHILD development ,INSULIN resistance ,METABOLIC syndrome ,JUVENILE diseases - Abstract
This study was performed to test whether children born small for gestational age (SGA) with catch-up growth (CUG) could be associated with the early development of insulin resistance and the β-cell dysfunction and to explore the impacts of height CUG and weight CUG on the insulin resistance in a Chinese population. A total of 30 children born SGA with CUG, 37 non-CUG (NCUG), and 42 born appropriate for gestational age (AGA) with normal height were recruited. Their fasting serum insulin, fasting glucose, insulin-like growth factor-1 (IGF-1) concentrations, and the homeostasis assessment model for insulin resistance (HOMA-IR) and β-cell function (HOMA%) were evaluated. The values of HOMA-IR in CUG SGA were significantly higher than that in NCUG SGA ( P = 0.002) and AGA children ( P = 0.036), respectively. Correlation analysis revealed that the concentrations of fasting serum insulin were positively correlated with IGF-1 ( r = 0.443, P = 0.001) and Δheight standard deviation score (SDS; r = 0.500, P = 0.002) in ≤6-year-old SGA children, but only with Δweight SDS ( r = 0.496, P = 0.030) in >6-year-old children. In conclusion, SGA children with CUG in height and a higher body mass index are prone to the development of insulin resistance. Higher levels of insulin were closely correlated with the postnatal height CUG in young SGA children and with the weight CUG in old children. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
44. Final height outcome of boys with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogue.
- Author
-
Hua-mei Ma, Zhe Su, Qiu-li Chen, Yan-hong Li, Hong-shan Chen, and Min-lian Du
- Subjects
STATURE ,PRECOCIOUS puberty ,LUTEINIZING hormone releasing hormone derivatives - Abstract
An abstract of the study "Final Height Outcome of Boys With Idiopathic Central Precocious Puberty Treated With Gonadotropin-Releasing Hormone Analogue" by Hua-mei Ma et al is presented.
- Published
- 2013
- Full Text
- View/download PDF
45. Serum aminoterminal proctype natriuretic peptide in girls with idiopathic central precocious puberty during GNRHA treatment.
- Author
-
Qiu-li Chen, Hua-mei Ma, Zhe Su, Yan-hong Li, Hong-shan Chen, and Min-lian Du
- Subjects
NATRIURETIC peptides ,PRECOCIOUS puberty ,LUTEINIZING hormone releasing hormone receptors - Abstract
An abstract of the study "Serum Aminoterminal Proctype Natriuretic Peptide in Girls With Idiopathic Central Precocious Puberty During GNRHA Treatment" by Qiu-li Chen et al is presented.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.